Prelude Therapeutics Announces $25 Million Private Placement
WILMINGTON, Del., Dec. 11, 2023 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (Nasdaq:PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced a private placement that the Company estimates will result in gross proceeds of approximately $25 million before deducting estimated offering expenses payable by the Company. Proceeds from the private placement will be used to primarily fund the continued advancement of its SMARCA2 portfolio, for working capital and general corporate purposes.
Related news for (PRLD)
- MoBot’s Stock Market Highlights – 10/21/25 02:00 PM
- Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
- Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025
- Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
- prelude therapeutics presents new data from smarca degrader portfolio at the 36th eortc-nci-aacr symposium